Clinical Trials · NCT06648031
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Lexaria Bioscience Corp.
- Enrollment
- 148
- Start date
- Dec 2024
- Locations
- 7 sites, Australia
- Primary endpoint
- Number of participants with treatment-emergent adverse events (TEAEs) and Serious adverse events